000307440 001__ 307440
000307440 005__ 20251231120303.0
000307440 0247_ $$2doi$$a10.3389/fbinf.2025.1705930
000307440 0247_ $$2pmid$$apmid:41424948
000307440 0247_ $$2pmc$$apmc:PMC12711791
000307440 037__ $$aDKFZ-2025-03039
000307440 041__ $$aEnglish
000307440 082__ $$a570
000307440 1001_ $$aUstjanzew, Arsenij$$b0
000307440 245__ $$aPredicting GD2 expression across cancer types by the integration of pathway topology and transcriptome data.
000307440 260__ $$aLausanne$$bFrontiers Media$$c2025
000307440 3367_ $$2DRIVER$$aarticle
000307440 3367_ $$2DataCite$$aOutput Types/Journal article
000307440 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767097164_1386405
000307440 3367_ $$2BibTeX$$aARTICLE
000307440 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307440 3367_ $$00$$2EndNote$$aJournal Article
000307440 520__ $$aThe disialoganglioside GD2 is a key cancer therapy target due to its overexpression in several cancers and limited presence in normal tissues. However, experimental assessment is technically challenging and not routinely available. We developed a computational framework that integrates reaction activity derived from transcriptomic data with the glycosphingolipid biosynthesis pathway to predict GD2 expression.We computed Reaction Activity Scores from transcriptomic data and weighted the reactions of a glycosphingolipid metabolic network, refining edge weights with topology-based transition probabilities to account for enzyme promiscuity. Cumulative activities of GD2-promoting and -mitigating reactions served as features in a Support Vector Machine (SVM) to model GD2-associated differences between neuroblastoma and normal tissue. SVM decision values were used as a continuous proxy for GD2 expression. We validated the predicted GD2 scores across independent datasets by comparing them with literature-reported values and flow-cytometric confirmation of a model-predicted high-GD2 tumor. Copy-number alteration (CNA) data were integrated to identify candidate genomic biomarkers of GD2-positive samples.Our SVM-based GD2 score achieved balanced accuracy of 0.80 with a linear kernel, selected due to reduced overfitting risk and interpretability, while matching the accuracy of more complex kernels. The model transferred reliably across six independent RNA-seq datasets and reproduced known GD2 expression patterns, outperforming a two-gene signature in capturing subtype-specific heterogeneity and avoiding overestimation in normal brain tissue. Pan-cancer analyses revealed heterogeneous GD2 expression in several cancer subtypes. Notably, we experimentally confirmed high GD2 expression in clear cell sarcoma of the kidney, consistent with model predictions. CNA analysis implicated B4GALNT1 amplification as a GD2-promoting factor in dedifferentiated liposarcoma. To facilitate adoption of our approach, we developed GD2Viz, an R package with an interactive Shiny application for score computation, visualization, and analysis of user data.Our computational framework provides a robust, interpretable, biologically grounded predictor of GD2 expression, offering greater consistency and clinical interpretability over existing gene-based signatures. Importantly, with over 20 GD2-directed trials ongoing, our approach may help prioritize tumor entities with high GD2 levels, delineate candidate patient subgroups, and generate testable hypotheses in underexplored cancers, thereby supporting patient stratification and eligibility screening for clinical trials.
000307440 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000307440 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307440 650_7 $$2Other$$aGD2 prediction
000307440 650_7 $$2Other$$abiomarker
000307440 650_7 $$2Other$$acancer subtypes
000307440 650_7 $$2Other$$aganglioside
000307440 650_7 $$2Other$$ametabolic network
000307440 650_7 $$2Other$$areaction activity score
000307440 650_7 $$2Other$$asupport vector machine
000307440 650_7 $$2Other$$atranscriptome analysis
000307440 7001_ $$aMarini, Federico$$b1
000307440 7001_ $$aWagner, Saskia$$b2
000307440 7001_ $$aWingerter, Arthur$$b3
000307440 7001_ $$0P:(DE-He78)a928ded2085c8911822370cad0b4a728$$aSandhoff, Roger$$b4$$udkfz
000307440 7001_ $$0P:(DE-HGF)0$$aFaber, Jörg$$b5
000307440 7001_ $$0P:(DE-HGF)0$$aParet, Claudia$$b6
000307440 773__ $$0PERI:(DE-600)3091287-8$$a10.3389/fbinf.2025.1705930$$gVol. 5, p. 1705930$$p1705930$$tFrontiers in bioinformatics$$v5$$x2673-7647$$y2025
000307440 909CO $$ooai:inrepo02.dkfz.de:307440$$pVDB
000307440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a928ded2085c8911822370cad0b4a728$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000307440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000307440 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000307440 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000307440 9141_ $$y2025
000307440 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-10-07T08:48:42Z
000307440 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-10-07T08:48:42Z
000307440 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-10-07T08:48:42Z
000307440 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-10-07T08:48:42Z
000307440 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000307440 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000307440 9201_ $$0I:(DE-He78)A411-20160331$$kA411$$lLipid-Pathobiochemie$$x0
000307440 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x1
000307440 980__ $$ajournal
000307440 980__ $$aVDB
000307440 980__ $$aI:(DE-He78)A411-20160331
000307440 980__ $$aI:(DE-He78)FM01-20160331
000307440 980__ $$aUNRESTRICTED